2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Marijuana Abuse
3
Neoplasms
2
Epilepsy
2
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Pancreatic Cancer Non-resectable
1
Pain
1
Opioid-Related Disorders
1
Neurodevelopmental Disorders
1
Multiple Sclerosis
1
Marijuana Use
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
Carcinoma, Hepatocellular
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Interventions
fludarabine
4
Cyclophosphamide
4
Specimen Handling
2
Nivolumab
2
Natalizumab
2
Interferon beta-1b
2
Fingolimod Hydrochloride
2
Blood Specimen Collection
2
teriflunomide
1
nabiximols
1
gadobutrol
1
gadobenic acid
1
cabozantinib
1
Surveys and Questionnaires
1
Respiratory Therapy
1
Registries
1
Platinum Compounds
1
Platelet Transfusion
1
Plasma Exchange
1
Phlebotomy
1
OM 89
1
Mn-PyC3A
1
Medical Marijuana
1
Magnetic Resonance Spectroscopy
1
Magnetic Resonance Imaging
1
Ipilimumab
1
Interferon beta-1a
1
Injections
1
Gadolinium DTPA
1
Fish Oils
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Sclerosis
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled